EGFR
16 articles
Industry NewsSummit Therapeutics / AkesoBioSpace
FDA rejects Summit's ivonescimab in EGFR-mutated lung cancer, citing missing survival benefit
- FDA issued a complete response letter for ivonescimab plus chemotherapy in EGFR-mutated NSCLC after TKI therapy, which would have been the first US approval of a PD-1xVEGF bispecific.
- The agency said progression-free survival gains without a statistically significant overall survival benefit do not show a positive benefit-risk profile; HARMONi missed its OS endpoint, and Summit's September follow-up analysis did not change that.
- Summit says it will keep building evidence across several NSCLC settings and gave no next step for this indication; partner Akeso already markets the drug in China.
The rejection was widely expected, and the lesson is about trial design: a PFS-only win in a post-TKI setting will not clear today's FDA. The bigger pivot is the Western first-line HARMONi-3 readout, which now carries the whole US thesis, and the combination partners lined up with Summit (AstraZeneca, Pfizer, Revolution Medicines) are holding options, not commitments.
PharmacologyScience Translational Medicine
Chemotherapy-induced fibroblast switch fuels pancreatic cancer resistance
- Single-cell profiling of pancreatic tumors showed that albumin-bound paclitaxel plus gemcitabine shifts cancer-associated fibroblasts from myofibroblastic to inflammatory states and expands a TMEM100+ subset in nonresponders.
- Paclitaxel engages IL-2–STAT5 signaling to induce TMEM100; these fibroblasts secrete amphiregulin, which activates EGFR on tumor cells and promotes resistance.
- Genetic removal of TMEM100+ fibroblasts in mice reversed the switch and improved chemotherapy response, nominating them as a target.
Ablating TMEM100+ fibroblasts in mice shows necessity, not druggability, and TMEM100 itself looks like a poor handle. The tractable node is AREG-EGFR, where EGFR inhibitors already exist, though erlotinib's modest benefit in pancreatic cancer tempers expectations. The decisive experiment is paired pre/post-treatment biopsies plus nab-paclitaxel combined with EGFR or ADAM17 blockade, tracking CAF plasticity.
PharmacologyScience Translational Medicine
Adding chemo to osimertinib does not stop small cell transformation in high-risk EGFR lung cancer
- A prospective trial gave first-line osimertinib with platinum and etoposide to EGFR-mutant lung adenocarcinoma patients carrying TP53/RB1 co-mutations, who are prone to small cell transformation.
- Despite the SCLC-directed chemotherapy, nearly half of the small cohort still transformed.
- Genomic and single-cell profiling showed plasticity, including mesenchymal and squamous states, tied to progressive RB pathway loss, altered chromatin accessibility and neuronal and EMT programs, intensified by osimertinib.
If SCLC-style chemo can't hold back transformation, the problem is likely lineage plasticity rather than an untreated small cell clone, so the next step is testing the drivers directly: RB pathway restoration, or epigenetic and neuronal-program inhibition. Without an osimertinib-alone comparator, "nearly half" is hard to read against baseline transformation risk. Serial biopsies or ctDNA would show whether RB loss precedes transformation.
PharmacologyBiochemical Pharmacology
Why Cetuximab Stops Working in Head and Neck Cancer: ERK Reactivation at the Center
- Cetuximab is the only approved molecularly targeted agent against a tumor receptor in head and neck squamous cell carcinoma, yet response rates are low and resistance is common.
- The review groups resistance into EGFR alterations, compensatory parallel pathways and reactivation of PI3K/Akt and Ras/ERK signaling.
- It treats ERK as the integrator of genetic, epigenetic and adaptive resistance.
Framing ERK as the convergence point is attractive because it suggests a common combination partner, but ERK reactivation is a readout of many upstream events and clinical ERK-pathway combinations have been hard to tolerate. The missing piece is patient-level data on which mechanism operates in which tumor. Without a biomarker that predicts the escape route, the combination trials will stay unselected.
Industry NewsJohnson & JohnsonEndpoints News
FDA Gives J&J's Rybrevant Faspro Accelerated Approval in Head and Neck Cancer
- The FDA granted accelerated approval to subcutaneous amivantamab (Rybrevant Faspro) for recurrent or metastatic head and neck squamous cell carcinoma that progressed after platinum chemotherapy and a PD-(L)1 antibody; HPV-associated oropharyngeal disease is excluded.
- It rests on a single-arm cohort of the Phase 1b/2 OrigAMI-4 study, with confirmatory trials required; the FDA called it the first new drug for this setting in a decade.
This is the first indication outside lung cancer for the EGFR/MET bispecific, and a single-arm response-rate approval means the Phase 3 OrigAMI-5 first-line study now carries the franchise's credibility. Cetuximab remains the comparator everyone will cite; with no randomized data, the open question is how much of the response translates into survival.
Computational & AIJournal of Chemical Theory and Computation
Predicting mutation-driven conformational shifts from one MD run
- Reweights one reference MD ensemble, state by state, to predict how a mutation redistributes conformational populations, avoiding a fresh converged simulation for each variant.
- Built-in diagnostics flag predictions the sampled data cannot support.
- Benchmarked on model peptides, a miniprotein, T4 lysozyme and the EGFR kinase domain; applicable only where the reference landscape is well sampled.
If the reweighting holds, this is the cheap triage step I'd want before spending alchemical FEP budget on a mutant panel: rank variants by predicted population shift, then run full simulations only on the ones that matter. The catch is that it's only as good as the reference run's coverage, so the built-in diagnostics matter more than any benchmark number. I'd test it first on a kinase DFG-in/out question where we already have data.
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
Linker design rules for EGFR ATP-allosteric bivalent inhibitors
- Studies ATP-site/allosteric bivalent EGFR inhibitors, where two ligands bound in neighbouring pockets are joined by a linker.
- A systematic SAR series shows that both linker length and attachment points can drive large potency improvements.
- Structural data and simulations point to maximal linker flexibility as the key design criterion, offering a framework that extends to fragment-based drug discovery.
Linker flexibility winning out is the interesting part: for a bivalent ATP-site/allosteric binder, I'd expect a rigid, pre-organized linker to pay off, so this suggests the two pockets are only loosely coupled. Attachment-point sensitivity is what I'd mine first. I'd want selectivity over WT EGFR and the molecular weight/permeability cost before calling it tractable.
Industry NewsAstraZeneca / HUTCHMEDEndpoints News
AstraZeneca's Tagrisso plus Orpathys aims to keep EGFR lung cancer patients on Tagrisso after resistance
- At ESMO 2026 AstraZeneca presented data for Tagrisso (osimertinib) plus Orpathys (savolitinib) in EGFR-mutated non-small cell lung cancer that has become resistant to Tagrisso.
- The SAFFRON Phase 3 enrolled MET-driven patients; August toplines reported better progression-free and overall survival than platinum chemotherapy.
- A US filing has been submitted, and the combination is already approved in China.
MET amplification is a leading way Tagrisso fails, so a combination that lets patients stay on the backbone gives AstraZeneca a lifecycle play on its biggest lung franchise. The market is narrow, since it depends on testing for MET-driven resistance, and rivals with EGFR-MET bispecifics are chasing the same patients.
PharmacologyBritish Journal of Pharmacology (Wiley)
Review: measuring covalent inhibitor kinetics and linking them to in vivo effect
- Lead selection leans on equilibrium IC50 values, which ignore how drug and target levels shift over time; this matters most for irreversible covalent drugs.
- The review surveys assays for kinact and KI: progress curves, multi-timepoint IC50 fitting for library triage, mass spectrometry for adducts and sites, SPR/NMR, and washout experiments for reversibility and residence time.
- It then links these rates to pharmacology via protein turnover, target vulnerability and pharmacokinetics, using BTK, JAK3, KRAS G12C and EGFR cases.
On a covalent hit, an IC50 from a single timepoint says little, because potency drifts with incubation time and ranking by it can bury the compound with the best kinact/KI. Translation is the harder part: in vivo occupancy depends on how fast the target is resynthesized, so a fast-turnover protein can blunt even a well-optimized warhead. Measure turnover before trusting the kinetics.
Medicinal ChemistryEuropean Journal of Medicinal Chemistry
Review maps covalent kinase inhibitors across EGFR, BTK, FGFR and JAK3
- This is a review article, not a primary study, covering 35 approved and investigational covalent kinase inhibitors.
- It focuses on four families that target a non-catalytic cysteine near the ATP pocket: EGFR (Cys797), BTK (Cys481), FGFR (Cys488) and JAK3 (Cys909).
- Each inhibitor is discussed for discovery history, binding mode, SAR, indications and synthesis, along with off-target toxicity and acquired resistance such as EGFR C797S.
Four cysteines, four very different risk profiles. Cys481 in BTK and Cys797 in EGFR are well-validated handles, but the C797S escape mutation shows the weakness: lose the nucleophile and the whole warhead strategy collapses, so reversible or allosteric backups matter. JAK3's Cys909 is the interesting one, since it can buy isoform selectivity that ATP-site binders struggle with, though acrylamide reactivity across the kinome remains the tox question.
Medicinal ChemistryACS Medicinal Chemistry Letters (ACS)
Crystal structures show how CNS-oriented EGFR TKIs gain potency, not just brain exposure
- Several EGFR TKIs redesigned for blood-brain barrier penetration were studied by X-ray crystallography and potency assays.
- The BBB-enhancing groups engage varied regions of the EGFR kinase domains, and biochemical and cellular potency generally improved.
- Salt-bridge-forming moieties combined with certain halogen substitutions worked best, pointing to a 'two-for-one' design logic.
CNS exposure and potency are usually traded off against each other, so a crystallographic case that the same polar or basic handle can buy both is useful. The salt-bridge-plus-halogen pairing is a concrete design rule I could try on my own kinase series. It does not address efflux or unbound brain concentrations, which still decide whether it works in a patient.
Industry NewsArriVent BioPharmaFierce Biotech
ArriVent's first-line EGFR exon 20 NSCLC phase 3 misses its primary endpoint
- Fierce Biotech reports that ArriVent's phase 3 FURVENT trial of the EGFR inhibitor firmonertinib missed its primary progression-free survival endpoint by blinded central review in first-line EGFR exon 20 insertion NSCLC.
- The higher dose showed only a modest numerical edge over platinum chemotherapy and the lower dose did numerically worse, while investigator-assessed results looked more favorable.
- ArriVent's shares fell sharply on the news.
A small central-review margin over chemo, in a setting where J&J's Rybrevant-plus-chemo regimen has already set a higher bar, leaves firmonertinib hard to position in exon 20. The investigator-versus-central gap gives ArriVent a regulatory conversation but a thin commercial story. The PACC-mutation ALPACCA study now looks like the company's real value driver.
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
A macrocyclic BI-4020-based PROTAC degrades C797S-resistant EGFR
- HQY1480 is a PROTAC built on the macrocyclic fourth-generation EGFR inhibitor BI-4020, with the linker and E3 ligand optimized systematically.
- It degraded several clinically relevant EGFR mutants at low nanomolar concentrations, and proteomics showed no detectable off-target degradation.
- It outperformed BI-4020 in xenografts, including osimertinib-resistant models, and degraded EGFR in patient-derived xenografts.
Starting from a macrocycle rather than a classical TKI is the smart move: it sidesteps the poor PK and selectivity that EGFR PROTACs usually inherit from their warheads. I'd want to see how the degrader holds up against compound-specific resistance mutations, and whether the favorable PK survives scale-up beyond mouse.
Industry NewsHUTCHMED / GSKEndpoints News
GSK licenses HUTCHMED's first-in-class KRAS-EGFR conjugate HMPL-A830 in deal worth up to $1.3B
- HUTCHMED and a GSK subsidiary signed an exclusive development and license agreement for HMPL-A830, described as a first-in-class KRAS-EGFR Antibody-Targeted Therapy Conjugate (ATTC).
- HMPL-A830 pairs a highly selective, potent small-molecule KRAS inhibitor payload with an anti-EGFR antibody, delivering the inhibitor selectively to EGFR-expressing tumor cells while also blocking EGFR signaling.
- GSK gains worldwide development and commercialization rights excluding Mainland China, Hong Kong, Macau and Taiwan, which HUTCHMED retains.
- Deal terms: $110 million upfront, up to $1.295 billion in additional development, regulatory and commercial milestone payments, plus tiered royalties on net sales.
- HUTCHMED will conduct the global Phase 1 program, expected to start in H2 2026, after which GSK takes over subsequent clinical development and commercialization.
- Initial clinical development will focus on colorectal, pancreatic and lung cancers.
Another Western major fills its oncology pipeline via China-origination rather than in-house discovery — GSK joins a fast-growing queue of ADC/conjugate deals mining HUTCHMED's pipeline for de-risked-but-early assets. The math is telling: $110M upfront against a $1.295B ceiling is roughly 8.5% at signing — real conviction, heavily hedged, standard for a preclinical/Phase 1 asset where GSK is paying mostly for optionality until clinical data lands. The ATTC design — a small-molecule KRAS payload riding an EGFR antibody — is a genuinely differentiated angle in an overcrowded KRAS field, avoiding classic cytotoxic-ADC toxicity while adding tumor-selective targeting. And HUTCHMED keeping Greater China rights again signals its now-familiar playbook: license out ex-China, retain commercial control at home.
Medicinal ChemistryJournal of Medicinal Chemistry (ACS)
Novel VHL-Recruiting PROTACs Degrade Mutant EGFR and Show Efficacy in NSCLC Models
- Researchers designed VHL-recruiting PROTAC degraders targeting EGFR, aiming to overcome acquired resistance to conventional EGFR kinase inhibitors in non-small cell lung cancer (NSCLC).
- Lead compounds C4 and D4 achieved potent, selective, and durable degradation of the EGFR Del19 and L858R resistance mutants.
- C4 induced cell cycle arrest and apoptosis, showed subnanomolar antiproliferative activity, and produced significant tumor regression in an HCC827 xenograft model at low intravenous doses on a reduced twice-weekly schedule.
- D4 was orally bioavailable and blood-brain barrier penetrant, and oral dosing completely halted tumor growth in vivo.
- The findings support a degradation-based strategy, rather than conventional inhibition, as a route to next-generation EGFR-directed therapies with potential central nervous system relevance.
D4 clearing both the oral bioavailability and blood-brain-barrier bars is the real headline here, more than the VHL-EGFR chemistry itself — most VHL degraders are 800-1000 Da PEG-linked bricks, gorgeous in a dish, DOA as an oral CNS drug. That's the developability wall this class has been stuck at. C4's profile reads more like a conventional IV PROTAC: subnanomolar antiproliferative potency and regression at low twice-weekly doses is a solid therapeutic index, but the reduced dosing schedule signals they're still managing catalytic turnover and clearance, not solving it outright. Degrading Del19/L858R instead of inhibiting them sidesteps the secondary-mutation resistance that keeps eroding osimertinib responses. If selectivity holds against WT EGFR in vivo, this is a real next-gen chemotype for NSCLC, not just a mechanistic proof-of-concept.
Medicinal ChemistryJournal of the American Chemical Society (ACS)
Antibody-Guided PROTAC Conjugate Blocks Tumor-Stroma Crosstalk by Silencing Extracellular Vesicles
- Researchers built Ctx-ETAC, a degrader-antibody conjugate pairing the approved EGFR antibody cetuximab with an engineered PROTAC payload, attached via a bioorthogonal reaction at a defined, controlled ratio per antibody.
- Its PROTAC payload pairs an indomethacin-derived COX-2 ligand with a VHL-recruiting peptide via a cathepsin B-cleavable linker, releasing the degrader selectively inside EGFR-positive tumor cells and activated fibroblasts.
- Degrading COX-2 in both cell types substantially curtails extracellular vesicle secretion, severing a key tumor-stroma signaling channel and nudging fibroblasts toward a quiescent, less tumor-supportive state.
- In a lung cancer xenograft model, Ctx-ETAC outperformed cetuximab alone in restraining tumor growth without added systemic toxicity, supporting microenvironment-targeted degradation as a therapeutic strategy.
Finally, a DAC that isn't just "ADC with a cooler payload" — swapping a cytotoxin for a VHL-PROTAC means efficacy doesn't hinge on brute-force poisoning of every internalized antibody; you get catalytic, event-driven target destruction instead. Smart target choice: COX-2 isn't the oncogenic driver, it's stromal plumbing. Cutting EV secretion to defuse tumor-fibroblast crosstalk instead of chasing EGFR resistance mutations directly is a genuinely different SAR logic than the usual "degrade the driver" playbook. Chemistry-wise, nothing exotic — indomethacin-COX-2 ligand, VHL peptide, cathepsin B-cleavable linker, defined-DAR bioorthogonal attachment. That's the point: boringly tractable, which is exactly what a translatable conjugation platform should look like. Real question is whether COX-2/EV silencing holds up in a fibroblast-rich, resistant tumor, not just a clean xenograft — but as a proof that microenvironment-directed degradation is maturing past a concept, this is convincing.